Philadelphia-based Orchestra Life Sciences, a technical consultancy providing strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare diseases, recently announced it is expanding its European presence.
Expansion will strengthen the company’s ability to support advanced therapy and radiopharmaceutical programs worldwide and reflects a growing demand for integrated execution, infrastructure readiness, and manufacturing strategy.
“Orchestra has been supporting clients engaged in the European radiopharmaceutical market for some time, and we continue to see strong momentum across the region,” Emilie Pelletier, Orchestra Life Sciences CEO and co-founder, said. “As programs scale and become increasingly global, we want to be able to better support our clients on the ground. We are excited to establish our presence in Europe and to do so with Vinod’s deep experience in nuclear medicine and complex program execution.”
Vinod Ramnandanlal will serve as Orchestra Life Sciences Europe president and managing director and will be tasked with overseeing regional strategy and execution, and working closely with clients and partners to support advanced therapy programs across Europe and globally. Ramnandanlal has more than a decade of board-level and executive experience in Europe.
Orchestra Life Sciences specializes in engineering solutions, operational excellence, and quality compliance services for advanced therapy manufacturing facilities.